Interleukin Genetics

ilgenetics.com

Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. The products empower individuals and their healthcare providers to manage prevention and treatment of chronic diseases through genetics-based insights and actionable guidance. Interleukin Genetics’ lead products include its proprietary ILUSTRA™ Inflammation Management Program and its Inherent Health® line of genetic tests.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Recipharm | January 04, 2021

news image

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More

Cell and Gene Therapy

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

news image

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

news image

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More

LESAFFRE AND RECOMBIA BIOSCIENCES ANNOUNCES STRATEGIC PARTNERSHIP TO ADVANCE INNOVATIVE GENE EDITING TECHNOLOGY

Recombia Biosciences | November 02, 2020

news image

Recombia Biosciences announces the launch of operations in Brisbane, California. The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. With its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in pa...

Read More
news image

Medical

RECIPHARM AND MODERNA FINALIZE AGREEMENT TO SUPPORT FORMULATION AND FILL-FINISH A PART OF THE MODERNA COVID-19 VACCINE SUPPLY OUTSIDE OF THE U.S.

Recipharm | January 04, 2021

Moderna, Inc. (NASDAQ:MRNA), biotechnology organization spearheading courier RNA (mRNA) therapeutics and vaccines, and Recipharm (STO: RECI-B), a main contract development and manufacturing organization (CDMO), today reported that they have agreed to help detailing and fill-finish a part of the Moderna COVID-19 Vaccine supply outside of the U.S. The action will be acted in Recipharm's medication item producing office located in France. Subject to regulatory approval of the imm...

Read More
news image

Cell and Gene Therapy

Y-BIOLOGICS AND PIERRE FABRE ANNOUNCES STRATEGIC PARTNERSHIP IN THE FIELD OF IMMUNO-ONCOLOGY RESEARCH

Y-Biologics | November 23, 2020

The South Korean biotech organization Y-Biologics and the French pharmaceutical group Pierre Fabre have declared their arrangements to frame a key association in the field of immuno-oncology research. The choice has been recognized through a letter of aim endorsed by the two players and will be affirmed in the coming a very long time through an itemized arrangement. The joint effort is set to run for a very long time, with the chance of a two-year expansion. Y-Biologics, which spe...

Read More
news image

Medical

TGEN SELECTS MEMVERGE TO ACCELERATE IDIOPATHIC PULMONARY FIBROSIS RESEARCH DISCOVERY WITH BIG MEMORY TECHNOLOGY

MemVerge | March 21, 2022

MemVerge™, the pioneers of Big Memory software, today announced that TGen, the Translational Genomics Research Institute, an affiliate of City of Hope, has selected MemVerge Memory Machine Big Memory virtualization software to accelerate time to discovery for Idiopathic Pulmonary Fibrosis (IPF), a disease which affects 100,000 people annually in the U.S. Using MemVerge technology, TGen is able to dramatically speed analytical processing by nearly 36% for single-cell RNA sequencing. ...

Read More
news image

LESAFFRE AND RECOMBIA BIOSCIENCES ANNOUNCES STRATEGIC PARTNERSHIP TO ADVANCE INNOVATIVE GENE EDITING TECHNOLOGY

Recombia Biosciences | November 02, 2020

Recombia Biosciences announces the launch of operations in Brisbane, California. The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. With its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in pa...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us